366 related articles for article (PubMed ID: 23689832)
1. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
[TBL] [Abstract][Full Text] [Related]
3. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
4. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
5. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.
Moestue SA; Dam CG; Gorad SS; Kristian A; Bofin A; Mælandsmo GM; Engebråten O; Gribbestad IS; Bjørkøy G
Breast Cancer Res; 2013 Feb; 15(1):R16. PubMed ID: 23448424
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.
Floc'h N; Kinkade CW; Kobayashi T; Aytes A; Lefebvre C; Mitrofanova A; Cardiff RD; Califano A; Shen MM; Abate-Shen C
Cancer Res; 2012 Sep; 72(17):4483-93. PubMed ID: 22815528
[TBL] [Abstract][Full Text] [Related]
10. The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.
Ji D; Zhang Z; Cheng L; Chang J; Wang S; Zheng B; Zheng R; Sun Z; Wang C; Zhang Z; Liu R; Zhang X; Liu X; Wang X; Li J
PLoS One; 2014; 9(1):e85116. PubMed ID: 24416349
[TBL] [Abstract][Full Text] [Related]
11. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
[TBL] [Abstract][Full Text] [Related]
12. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
13. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
Li T; Yang Y; Li X; Xu C; Meng L
Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
16. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
[TBL] [Abstract][Full Text] [Related]
17. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
18. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.
He X; Wang Y; Zhu J; Orloff M; Eng C
Cancer Lett; 2011 Feb; 301(2):168-76. PubMed ID: 21168265
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]